SELLAS Life Sciences Group Inc. (SLS), whose shares hit an all-time low of $0.50 yesterday, has a couple of catalysts to watch this year.
The company's lead product candidate, Galinpepimut-S, licensed from Memorial Sloan-Kettering Cancer Center, is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com